Hepion tumbles after discontinuing trial for fatty liver disease treatment

** Shares of drug developer Hepion Pharmaceuticals HEPA fall 33.8% to $1.30 in extended trading

** Company says it is winding down a mid-stage trial evaluating the drug rencofilstat for the treatment of a fatty liver disease known as non-alcoholic steatohepatitis

** There is low probability of generating relevant efficacy data given its current cash resources - Hepion

** Company is continuing to explore strategic alternatives

** Up to last close, stock down 86.4% in last 12 months